Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Key Milestones in the Endocrine Peptide Test Market’s Growth Trajectory From 2025 To 2034?
There has been a considerable growth in the endocrine peptide test market size over the last few years. The market, which is projected to jump from $9.11 billion in 2024 to $9.95 billion in 2025, is set to experience a Compound Annual Growth Rate (CAGR) of 9.3%. This notable growth during the historical period can be connected to factors such as an increase in government funding, a high prevalence of diabetes, dwindling immunity levels worldwide, an increased likelihood of developing chronic diseases, and enhanced government initiatives.
The market size of the endocrine peptide test is anticipated to experience robust growth in the forthcoming years, with predictions estimating a growth to$13.9 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. This expected growth during the forecast period is caused by a surge in the demand for endocrine peptide test, an increase in research and innovation activities, rise in diseases associated with lifestyle, growing elderly population, and heightened occurrence of diabetes in the community at large. The forecast period is also projected to witness major trends such as improvement in the methods of endocrine testing, technological advancements in products, enhanced research and development activities for novel testing methods, growing product approval rates, and a switch towards preventative healthcare.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16675&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Endocrine Peptide Test Market?
The escalating occurrence of diabetes is anticipated to spur the expansion of the endocrine peptide test market in the future. Diabetes is a collection of diseases that cause elevated levels of blood sugar (glucose). The rise in diabetes cases is attributed to elements such as poor eating habits, inactive lifestyles, hereditary predisposition, and an elderly demographic. Endocrine peptide tests, like hemoglobin A1c, fasting plasma glucose, and C-peptide tests, are employed in diabetes management to identify the disease, check glucose levels, and evaluate insulin output and responsiveness. For example, the National Health Service (NHS), a government department in the UK, reported in June 2024 that there was a considerable increase in the number of individuals under 40 diagnosed with diabetes, with figures leaping from 173,166 in 2022 to 216,440 in 2023. This rapid increase illuminates a worrisome pattern of escalating diabetes occurrence in younger demographics. Consequently, the swelling incidence of diabetes is fuelling the growth of the endocrine peptide test market.
Which Key Market Segments Comprise the Endocrine Peptide Test Market and Drive Its Revenue Growth?
The endocrine peptide testmarket covered in this report is segmented –
1) By Test-Type: Dehydroepiandrosterone Sulphate; Progesterone; Luteinizing Hormone; Thyroid Prolactin; Oestradiol; Human Chorionic Gonadotropin; Thyroid-Stimulating Hormone; Other Test-Types
2) By Technology: Mass Spectroscopy; Immunoassay; Chromatography; Nucleic Acid Based; Other Technologies
3) By End-User: Clinics; Healthcare Centers; Hospitals; Commercial Laboratories
Subsegments:
1) By Dehydroepiandrosterone Sulphate (DHEA-S): Immunoassay Tests; Enzyme-Linked Immunosorbent Assay (ELISA); Radioimmunoassay (RIA)
2) By Progesterone: Immunoassay Tests; Chemiluminescence Assays; ELISA Tests
3) By Luteinizing Hormone (LH): Immunoassay Tests; Enzyme Immunoassay (EIA); Radioimmunoassay (RIA)
4) By Thyroid Prolactin: Immunoassay Tests; Chemiluminescence Assays; Radioimmunoassay (RIA)
5) By Oestradiol: Immunoassay Tests; Enzyme-Linked Immunosorbent Assay (ELISA); Radioimmunoassay (RIA)
6) By Human Chorionic Gonadotropin (hCG): Immunoassay Tests; Chemiluminescence Assays; Enzyme Immunoassay (EIA)
7) By Thyroid-Stimulating Hormone (TSH): Immunoassay Tests; Radioimmunoassay (RIA); Enzyme-Linked Immunosorbent Assay (ELISA)
8) Other Test-Types: Cortisol; Insulin; Growth Hormone (GH); Parathyroid Hormone (PTH)
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=16675&type=smp
Which Areas Are Leading Regions in the Endocrine Peptide Test Market Expansion Across the Globe?
North America was the largest region in the endocrine peptide test market in 2024. The regions covered in the endocrine peptide test market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Key Market Trends in theEndocrine Peptide Test Market Over the Coming Years?
Leading corporations in the endocrine peptide test market are developing advanced immunoassay testing systems to enhance the accuracy, sensitivity, and speed of endocrine peptide testing. The utilization of antibodies to identify and measure specific peptides in blood or urine samples by these testing systems provides vital data about hormone levels and endocrine function to healthcare professionals. For instance, in July 2023, Siemens Healthineers, a reputable healthcare services company based in Germany, introduced the Atellica CI Analyzer. This compact system is designed for immunoassay and clinical chemistry testing, including endocrine peptide assays. The analyzer boasts a reproductive endocrinology menu inclusive of anti-Mullerian hormone (AMH) for assessing ovarian reserve and sFlt-1 and PlGF (placental growth factor) to assist in evaluating the prognosis of preeclampsia. The Atellica CI Analyzer is crafted to provide quick, reliable results with a capacity of up to 1000 tests per hour. It facilitates workflow efficiency and adaptability to support labs in meeting their changing testing needs.
View the full report here:
https://www.thebusinessresearchcompany.com/report/endocrine-peptide-test-global-market-report
How Is the Endocrine Peptide Test Market Conceptually Defined?
Endocrine peptide test refers to a diagnostic test used to measure the levels of specific peptides (small proteins) in the blood or urine that are related to the functioning of the endocrine system. The primary aim of the endocrine peptide test is to diagnose and monitor endocrine disorders by measuring specific peptide hormones in the blood.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16675
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model